Slide 1: Alligator Bioscience AB
Alligator Bioscience AB September 2025 Committed to bringing forward innovative antibody-based immunotherapies for cancer patients
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates
Slide 3: Alligator Bioscience Overview
Alligator Bioscience Overview Phase 3 ready biotech company listed on Nasdaq Stockholm (ATORX) and focused on immuno-oncology: Pipeline of best-in-class agonistic anti-cd40 mono- and bispecific antibodies Lean and focused organization to bring mitazalimab towards Phase 3: Reorganization focuses reso
Slide 4: Advancing a diversified immuno-oncology pipeline
Advancing a diversified immuno-oncology pipeline Wholly-owned CD40-programs Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Mitazalimab Solid metastatic tumors, mAb CD40 initially pancreatic cancer ATOR-4066 Solid metastatic tumors bsAb CD40 & CEACAM5 Partnered programs Program Indi
Slide 5: Mitazalimab
Mitazalimab 5|
Slide 6: Pancreatic cancer
Pancreatic cancer Overview of patient journey and treatment landscape …potentially making it a 1L treatment opportunity with Mitazalimab is uniquely positioned for combination with chemo … in comparison to current metastatic PDAC manageable safety profile and improved survival as a high-prognosis th
Slide 7: Metastatic pancreatic cancer – significant medical need
Metastatic pancreatic cancer – significant medical need › +85k patients diagnosed with mPDAC annually in the US and EU5 › 5 year survival rate: 3-5% › Chemotherapy only option for 90-95% of metastatic patients › Median survival for chemotherapy: 8-11 months › Chemotherapies are associcated with seve
Slide 8: Mitazalimab designed for optimal therapeutic window
Mitazalimab designed for optimal therapeutic window Optimal binding epitope: Domain 1 on CD40 Best in class properties › Binds domain 1 on CD40: strong agonistic effect and FcγR- conditional CD40 agonism › Wild type IgG1: provides the right balance of immune activation/safety OPTIMIZE-1: positive Ph
Slide 9: OPTIMIZE-1
OPTIMIZE-1 A Phase 1b/2 trial with outstanding survival benefit in first-line pancreatic cancer › First line metastatic Pancreatic Adenocarcinoma › Patient population is representative of mPDAC › Primary Endpoint: ORR (RECIST 1.1) › Enrolment at 15 sites › Secondary Endpoints: DoR, PFS, OS, Safety,
Slide 10: Mitazalimab’s excellent safety profile allows sustained treatment
Mitazalimab’s excellent safety profile allows sustained treatment Observation Clinical relevance Premedication limited to anti-histamines Low incidence of Grade ≥2 infusion related and anti-leukotrienes reactions avoiding the need for corticosteroids. Mitazalimab can be safely combined with intensiv
Slide 11: Mitazalimab delivers deep and durable tumor responses
Mitazalimab delivers deep and durable tumor responses 100 100 Best overall response 80 80 Progressive Disease (PD) Stable Disease (SD) Partial Response (PR) 60 60 Complete Response (CR) 40 40 Change from baseline, % Depth of response (%) 20 20 0 0 -20 -20 -40 -40 -60 -60 -80 -80 -100 -100 Patients 3
Slide 12: Mitazalimab delivers superior long-term survival in mPDAC
Mitazalimab delivers superior long-term survival in mPDAC mDoR Mitazalimab + mFFX* 12.6 Patient status 900 µg/kg cohort FFX** 5.9 at cut-off 3 July 2025 mOS 14.9 › 2 patients still on treatment 11.1 › 10 patients in long-term follow-up months: 0 2 4 6 8 10 12 14 16 Trial completion 18-mo 37% › Sites
Slide 13: Mitazalimab induced activity associated with improved survival
Mitazalimab induced activity associated with improved survival Comprehensive multi-omic biomarker analysis performed Stroma related gene Activation of Treatment induced Mitazalimab signature (ECm) in immune cells that activation of myeloid traffics to the tumors at baseline tumor predicts Reduction
Slide 14: Advancing mitazalimab towards Phase 3 in mPDAC
Advancing mitazalimab towards Phase 3 in mPDAC › Disease-relevant mechanism of action › All needed toxicology studies completed › Phase 2 trials completed › Relevant efficacy and safety profile › Regulatory validation of non-clinical, CMC and clinical data › Regulatory agreement on registrational tr
Slide 15: Market potential (US and EU5)
Market potential (US and EU5) New Cases per Year US EU5 66,400 65,700 Pancreatic Cancer 43,100 Metastatic Disease 42,100 (65%) ECOG 0-1 30,200 1st line SoC 29,500 (70%) FFX 11,400 Treatment 11,200 (38%) ~22.5k addressable FFX treated patients in the US and EU5 annually Total addressable 1st line SoC
Slide 16: Several opportunities for label and indication expansion
Several opportunities for label and indication expansion › Gem/Nab-Pac in 1st line mPDAC Expand from CPOC in 1st line mPDAC Pancreatic › Locally advanced pancreatic cancer Safety established with FFX cancer › Resectable pancreatic cancer Mita + mFFX › Biliary tract cancer Similar tumor anatomy + imm
Slide 17: Mitazalimab
Mitazalimab Best-in-Class, Phase 3 ready, 2nd Gen CD40 Agonist › Second generation CD40 agonist, IgG1-wt human antibody with differentiated CD40 epitope binding Best-in-Class › “Universal” combination partner with SoC; chemotherapy or checkpoint inhibitors › Activation of antigen presenting cells Mo
Slide 18: ATOR-4066
ATOR-4066 18 |
Slide 19: ATOR-4066 – Alligator beyond mitazalimab
ATOR-4066 – Alligator beyond mitazalimab A mitazalimab follow-on candidate with potential for enhanced efficacy Mode of action Novel Mode of action › CEACAM5-conditional CD40 activation of DCs and macrophages › Enhanced DC uptake and presentation of neoantigen leading cross-priming of tumor specific
Slide 20: ATOR-4066 effectively targets diverse tumors
ATOR-4066 effectively targets diverse tumors Provides competitive edge over CEACAM5-targeting ADC and CD3 bsAb therapies Rapid effect on tumor growth CEACAM5 expression ATOR-4066 T Cell tumor day 10 2000 Days 10, 14 and 17 Tumor volume (mm3) 1500 DC 100 % CEACAM5+ tumor cells T Cell 1000 80 500 T Ce
Slide 21: ATOR-4066 summary
ATOR-4066 summary ATOR-4066 ▪ CD40 x CEACAM5 bispecific antibody bsAb profile ▪ Effective and unique tumor-specific T cell priming by engaging DCs with tumor debris ATOR-4066 ▪ Opportunity in multiple CEACAM5-expressing tumors Clinical development ▪ Combine with chemo and/or PD-1 in cold, macrophage
Slide 22: Other pipeline assets
Other pipeline assets 22 |
Slide 23: ALG.APV-527: A tumor-directed I-O therapy for 5T4+ tumors
ALG.APV-527: A tumor-directed I-O therapy for 5T4+ tumors Anti-4-1BB scFv Current status › Monotherapy dose escalation › Five dose levels tested – 0.1 mg/kg, 0.5 mg/kg, 2 mg/kg, 6 mg/kg, 12 mg/kg › 19 patients treated at 6 sites in the USA › Last patient off trial February 2025 Modified › Safety Fc
Slide 24: HLX22
HLX22 anti-HER2 antibody in development for several HER2-positive solid tumor types › Innovative anti-HER2 monoclonal antibody › Developed by Chinese Shanghai Henlius Biotech Inc., under a license from AbClon, Inc., following a discovery collaboration which grants Alligator a stake in future revenue
Slide 25: HLX22 (cont.)
HLX22 (cont.) anti-HER2 antibody in development for several HER2-positive solid tumor types › Alligator has no access to detailed study information, can only rely on what has been publicly communicated by Henlius › Alligator expects to receive the next development milestone within 6-12 months › Main
Slide 26: Technology
Technology 26 |
Slide 27: Neo-X-Prime – Myeloid-engager driving tumor immunity
Neo-X-Prime – Myeloid-engager driving tumor immunity Effective neoantigen-specific T cell priming Increased priming and Decreased suppressive Neo-X-Prime , a CD40-based activation of tumor environment by myeloid cell bispecific platform with specific T cells activation dual Mode of Action A. Tumor a
Slide 28: RUBY – for easy engineering of novel bsAb drug candidates
RUBY – for easy engineering of novel bsAb drug candidates Developed with the 6 drug development criteria in mind › RUBY is Alligator’s proprietary bispecific antibody (bsAb) format. › Allows for easy generation of novel bsAb candidate drugs with The 6 drug excellent properties that meet the 6 drug d
Slide 29: Financials
Financials 29 |
Slide 30: Latest quarterly financials
Latest quarterly financials › Expenses pertain mainly of cost for ongoing clinical trial and Phase 3 enabling activities (e.g. production of IMP) for mitazalimab, in addition to general operating costs › Reversal of participation in development relating to HLX 22 › Net financial items include intere
Slide 31: Shareholder list (holdings as of end August 2025)
Shareholder list (holdings as of end August 2025) Shareholders No of shares % Avanza Pension 3,922,110 11.3 Roxette Photo SA 1,987,412 5.7 Johan Zetterstedt 1,238,800 3.6 Nordnet Pension Insurance 1,238,385 3.6 Magnus Petersson 1,209,000 3.5 Sbakkejord AS 860,000 2.5 AB Gryningsstunden Förvaltning 8
Slide 32: Contact information
Contact information ir@alligatorbioscience.com Alligator Bioscience AB | Medicon Village, Scheeletorget 1, SE-223 81 Lund, Sweden | Phone: + 46 46 540 82 00 | www.alligatorbioscience.com